Clinical Trials Logo
  1. Home
  2. Refractory Mycosis Fungoides
  3. NCT03281811

Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides

Refractory Mycosis Fungoides Clinical Trial

Official title:
A Pilot Study of Photodynamic Therapy in Refractory Plaques and Tumors of Mycosis Fungoides

Clinical Trial Summary

This pilot phase II trial studies how well photodynamic therapy works in treating patients with mycosis fungoides that does not respond to treatment. Photodynamic therapy uses a drug, such as aminolevulinic acid hydrochloride, that becomes active when it is exposed to light. The activated drug may kill cancer cells.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the efficacy of photodynamic therapy (PDT) in refractory tumors and plaques of mycosis fungoides (MF). SECONDARY OBJECTIVES: I. To determine the effects of sequential PDT and radiation therapy (RT). II. To determine the side effect profile of PDT in MF. EXPLORATORY OBJECTIVES: I. To determine the quality of life during and after treatment. OUTLINE: Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks. After completion of study treatment, patients are followed up for up to 8 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03281811
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Early Phase 1
Start date November 13, 2017
Completion date August 12, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02978625 - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Phase 2
Active, not recruiting NCT03278782 - Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Phase 1/Phase 2
Recruiting NCT02702310 - Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
Terminated NCT03075553 - Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Phase 2
Recruiting NCT03011814 - Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Phase 1/Phase 2
Suspended NCT03432741 - Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Phase 1
Withdrawn NCT03373305 - Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Phase 1
Active, not recruiting NCT04074746 - Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Phase 1/Phase 2
Active, not recruiting NCT03598998 - Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Phase 1/Phase 2
Active, not recruiting NCT04541017 - Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Phase 1/Phase 2
Recruiting NCT03017820 - VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Phase 1